Pharmaceutical The renal cell carcinoma drug market will experience robust 3.7% annual growth from 2010 to 2020 in the leading markets of the USA, France, Germany, Italy, Spain, the UK and Japan, according to health care advisory firm Decision Resources. Market growth will be driven mainly by the uptake of GlaxoSmithKline's Votrient (pazopanib, the launches of premium-priced emerging therapies, rising treatment rates and an increase in the number of diagnosed patients. 11 December 2011